#Volixibat #primarysclerosingcholangitis #VISTAS Today, we announced that the VISTAS study, evaluating volixibat in patients with primary sclerosing cholangitis (PSC), met its primary endpoint, showing statistically significant and clinically meaningful reductions in pruritus
Never stop your medication without speaking to your GP or pharmacist
Patients should talk with their provider about long-term use, the possibility of weight regain if they stop the drug, and how to pair medication with diet, exercise, and other lifestyle changes to get safer, lasting results
Superparamagnetic iron oxide loaded Chitosan coated bilosomes for magnetic nose to brain targeting of Resveratrol
This triple-agonist profile is its defining pharmacological feature
Sima AA: Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data